New analyses reinforce long-term benefit of DARZALEX® (daratumumab) subcutaneous-based quadruplet regimen for patients with newly diagnosed multiple myeloma
Data from the Phase 3 CEPHEUS study show daratumumab-VRd significantly reduced the risk of progression or death by 49 percent vs VRd alone in transplant-ineligible newly diagnosed patients2
BEERSE, BELGIUM, June 03, 2025 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a Johnson & Johnson company, today announced data from two studies highlighting that DARZALEX® (daratumumab) subcutaneous (SC) formulation with bortezomib, lenalidomide and dexamethasone (daratumumab-VRd) demonstrated deep and sustained minimal residual disease (MRD) negativity rates, and improved long-term progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM), regardless of transplant status.1,2 Findings were highlighted as oral presentations of an analysis of sustained MRD in transplant-eligible patients from the Phase 3 PERSEUS study (Abstract #7501) and a subgroup analysis of transplant-ineligible patients in the Phase 3 CEPHEUS study (Abstract #7516) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.1,2
'Daratumumab-based quadruplet regimens are redefining frontline treatment in multiple myeloma, offering the potential for deeper, more durable responses from the start, bringing patients closer to long-term remission,' said Ester in't Groen, EMEA Therapeutic Area Head Haematology, Johnson & Johnson Innovative Medicine. 'The latest data presented at ASCO further support the role of the PERSEUS and CEPHEUS regimens as a standard of care in patients with newly diagnosed disease, regardless of transplant eligibility.'
A new analysis from the Phase 3 PERSEUS study shows the addition of daratumumab-VRd followed by a maintenance regimen of daratumumab SC with lenalidomide (daratumumab-R), led to improved and deepened rates of overall and sustained MRD negativity (10-5) compared to VRd induction and consolidation with R maintenance.1 At a median follow-up of 47.5 months, sustained MRD negativity (10-5) rates were more than doubled with daratumumab-VRd followed by daratumumab-R maintenance compared to VRd and R maintenance at both 12 months or longer (64.8 percent vs 29.7 percent; odds ratio, 4.42; 95 percent confidence interval [CI], 3.22–6.08; p<0.0001) and 24 months or longer (55.8 percent vs 22.6 percent; odds ratio [OR], 4.36, 95 percent CI, 3.15–6.05, p<0.0001).1
Among patients achieving sustained MRD negativity for 12 months or longer, the 48-month PFS rate for daratumumab-VRd followed by daratumumab-R maintenance was 95.3 percent compared to 94.2 percent for VRd and R maintenance (hazard ratio [HR], 0.83; 95 percent CI,0.3–2.3)—reinforcing the importance of achieving sustained MRD negativity for prolonged disease remission.1
'The data show that daratumumab-VRd followed by a daratumumab-R maintenance regimen is a highly effective treatment option for transplant-eligible patients with newly diagnosed multiple myeloma,' said Philippe Moreau, M.D., head of the Hematology Department, University Hospital Hôtel-Dieu, Nantes, France and presenting author.* 'The depth and durability of MRD negativity observed—paired with high rates of progression-free survival at four years—underscore the long-term benefit the daratumumab SC-based regimen can offer patients early in their treatment journey.'
Additional data from Phase 3 CEPHEUS study explore the benefits of daratumumab SC in transplant-ineligible patients across cytogenetic risk status
The post-hoc analysis of the Phase 3 CEPHEUS study focused exclusively on transplant-ineligible patients, reinforcing that adding daratumumab SC to VRd significantly deepens response and prolongs PFS compared to VRd alone in this patient population.2
At a median follow-up of 58.7 months, patients receiving daratumumab-VRd achieved markedly higher overall MRD negativity rates at the 10⁻⁵ sensitivity threshold with 60.4 percent vs 39.3 percent with VRd (OR, 2.37; 95 percent CI, 1.47–3.80; p=0.0004).2 Furthermore, treatment with daratumumab-VRd resulted in high MRD-negativity rates at the 10⁻⁶ threshold with 45.8 percent compared to 26.9 percent with VRd (OR, 2.28; 95 percent CI, 1.40–3.73; p=0.0010).2 These deeper responses translated into improved long-term outcomes, with 69.0 percent of patients remaining progression-free at 54-months when treated with daratumumab-VRd vs 48.0 percent with VRd (HR, 0.51; 95 percent CI, 0.35–0.74; p=0.0003).2 Overall survival (OS) numerically favoured daratumumab-VRd (HR, 0.66; 95 percent CI, 0.42–1.03, p=0.0682), with an even greater benefit observed after censoring for COVID-19-related deaths (HR, 0.55; 95 percent CI, 0.34–0.90, p=0.0159).2
Additional data presented at ASCO included a subgroup analysis of the CEPHEUS trial for both transplant-ineligible and deferred NDMM patients who were considered high-risk for cytogenetic abnormalities (Abstract #7529).3 At a median follow-up of 58.7 months, overall MRD negativity rate was improved for patients with standard risk in daratumumab-VRd vs VRd.3 Although rates of MRD negativity by treatment arm in patients with protocol-defined high-risk were comparable, PFS trended toward improvement with daratumumab-VRd.3
'Across multiple studies, the growing body of data on daratumumab-based regimens indicates impressive, deep responses and meaningful progression-free survival in patients with newly diagnosed multiple myeloma, including high-risk,' Jordan Schecter, M.D., Vice President, Disease Area Leader, Multiple Myeloma, Johnson & Johnson Innovative Medicine. 'These consistent results across patient populations, regardless of transplant eligibility, reinforce the role of daratumumab SC as a cornerstone of frontline therapy.' In the PERSEUS and CEPHEUS studies, the safety profiles were consistent with the known safety profile for daratumumab SC.1,2,3 Safety results of daratumumab-VRd in the PERSEUS study were previously reported in The New England Journal of Medicine.4 The most common haematologic adverse reactions (≥20 percent) in patients with multiple myeloma who received daratumumab-VRd vs VRd included neutropenia (69.2 percent vs 58.8 percent), thrombocytopenia (48.4 percent vs 34.3 percent), and anaemia (22.2 percent vs 20.7 percent).4 Similarly, in the CEPHEUS study, daratumumab-VRd showed no additional safety concerns in the transplant-ineligible subgroup compared with the intent to treat population.2 The most common Grade 3/4 haematologic treatment-emergent adverse events (TEAEs) were neutropenia (43.8 percent vs 31.7 percent), thrombocytopenia (30.6 percent vs 23.2 percent) and anaemia (12.5 percent vs 12.7 percent).2
About the PERSEUS and CEPHEUS studiesThe PERSEUS study (NCT03710603) is being conducted in collaboration with the European Myeloma Network as the sponsor.5 PERSEUS is an ongoing, randomised, open-label, Phase 3 study comparing the efficacy and safety of daratumumab, bortezomib, lenalidomide, and dexamethasone (daratumumab-VRd) and autologous stem cell transplant (ASCT) followed by D-R maintenance vs standard bortezomib, lenalidomide, and dexamethasone (VRd) and ASCT followed by R maintenance in patients with transplant eligible newly diagnosed multiple myeloma (NDMM) (n=355).4 The primary endpoint is progression-free survival (PFS), and secondary endpoints include overall complete response or better rate, overall minimal residual disease (MRD) negativity (in patients with complete response or better) and overall survival (OS).4 Daratumumab subcutaneous (SC) formulation was discontinued after at least 24 months of D-R maintenance therapy in patients who had a complete response or better and had sustained MRD negative status for at least 12 months.4 The median age is 61.0 (range, 32-70) years for patients in the daratumumab-VRd arm and 59.0 (range, 31-70) years for patients in the VRd arm.4 The study is being conducted in 13 countries in Europe and Australia.5 On 23 October 2024, an indication extension for daratumumab-VRd was approved by the European Commission for NDMM who are eligible for ASCT, based on the results of the PERSEUS study.6,7
CEPHEUS (NCT03652064) is an ongoing, randomised, open-label, Phase 3 study comparing SC daratumumab-VRd with standard VRd.8,9 The trial has enrolled 395 patients with NDMM who are either ineligible for stem cell transplantation (SCT) or for whom SCT is not planned.9 The primary endpoint is overall MRD-negativity rate.9 The minimum age for participation is 18 years for patients in both the daratumumab-VRd arm and VRd arm, with a median patient age of 70 (range 31-80).8 The study is being conducted in 13 countries across North America, South America and Europe.9 On 7 April 2025, an indication extension for daratumumab-VRd was approved by the European Commission for NDMM, based on the results of the CEPHEUS study.9,10
About daratumumab and daratumumab SC Johnson & Johnson is committed to exploring the potential of daratumumab for patients with multiple myeloma across the spectrum of the disease.
In August 2012, Janssen Biotech, Inc., a Johnson & Johnson company, and Genmab A/S entered a worldwide agreement, which granted Johnson & Johnson an exclusive licence to develop, manufacture and commercialise daratumumab. Since launch, daratumumab has become a foundational therapy in the treatment of multiple myeloma, having been used in the treatment of more than 618,000 patients worldwide.11 Daratumumab is the only CD38-directed antibody approved to be given subcutaneously to treat patients with multiple myeloma.12 Daratumumab SC is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme's ENHANZE® drug delivery technology.12
CD38 is a surface protein that is present in high numbers on multiple myeloma cells, regardless of the stage of disease.12 Daratumumab binds to CD38 and inhibits tumour cell growth causing myeloma cell death.12 Daratumumab may also have an effect on normal cells.12 Data across ten Phase 3 clinical trials, in both the frontline and relapsed settings, have shown that daratumumab-based regimens resulted in significant improvement in progression-free survival and/or overall survival.8,13,14,15,16,17,18,19,20
For further information on daratumumab, please see the Summary of Product Characteristics at: https://ec.europa.eu/health/documents/community-register/html/h1101.htm.
About Multiple MyelomaMultiple myeloma is currently an incurable blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow.21,22 In multiple myeloma, these malignant plasma cells continue to proliferate, accumulating in the body and crowding out normal blood cells, as well as often causing bone destruction and other serious complications.22 In the European Union, it is estimated that more than 35,000 people were diagnosed with multiple myeloma in 2022, and more than 22,700 patients died.23 Patients living with multiple myeloma experience relapses which become more frequent with each line of therapy 24,25 while remissions become progressively shorter.24,25,26 Whilst some patients with multiple myeloma initially have no symptoms, others can have common signs and symptoms of the disease, which can include bone fracture or pain, low red blood cell counts, fatigue, high calcium levels, infections, or kidney damage.27
About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow. and profoundly impact health for humanity.
Learn more at www.innovativemedicine.jnj.com/emea. Follow us at www.linkedin.com/company/jnj-innovative-medicine-emea. Janssen-Cilag International NV, Janssen Pharmaceutica NV, Janssen-Cilag Limited, Janssen Biotech, Inc., and Janssen Research & Development, LLC are Johnson & Johnson companies.
This press release contains 'forward-looking statements' as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of daratumumab. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialise, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes in behaviour and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned 'Cautionary Note Regarding Forward-Looking Statements' and 'Item 1A. Risk Factors,' and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at http://www.sec.gov/, http://www.jnj.com/ or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
*Philippe Moreau, M.D., head of the Hematology Department, University Hospital Hôtel-Dieu, Nantes, France, has provided consulting, advisory, and speaking services to Janssen-Cilag International NV; he has not been paid for any media work.
1 Moreau P, et al. Subcutaneous daratumumab (Dara) + bortezomib/lenalidomide/dexamethasone (VRd) with Dara + lenalidomide (DR) maintenance in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM): analysis of sustained minimal residual disease negativity in the phase 3 PERSEUS trial. Oral presentation. American Society of Clinical Oncology (ASCO) Annual Meeting; May 30 – June 3, 2025.2 Facon T, et al. Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of transplant-ineligible (TIE) patients in the phase 3 CEPHEUS study. Oral presentation. American Society of Clinical Oncology (ASCO) Annual Meeting; May 30 – June 3, 2025.3 Bahlis N.J, Daratumumab + bortezomib, lenalidomide, and dexamethasone (DVRd) vs VRd in transplant-ineligible (TIE)/transplant-deferred (TD) newly diagnosed multiple myeloma (NDMM): phase 3 CEPHEUS trial cytogenetic subgroup analysis. Poster presentation. American Society of Clinical Oncology (ASCO) Annual Meeting; May 30 – June 3, 2025.4 Sonneveld P, et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 2024; 390:301-313.5 ClinicalTrials.gov. Daratumumab, VELCADE (bortezomib), lenalidomide and dexamethasone compared to VELCADE, lenalidomide and dexamethasone in subjects with previously untreated multiple myeloma (Perseus). NCT03710603. Available at: https://www.clinicaltrials.gov/study/NCT03710603. Last accessed: May 2025.6 Rodríguez-Otero P, et al. Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): analysis of minimal residual disease (MRD) in the PERSEUS trial. 2024 American Society for Clinical Oncology (ASCO) Annual Meeting. June 3, 2024.7 Johnson & Johnson Innovative Medicine EMEA. DARZALEX® (daratumumab)-SC based quadruplet regimen approved by the European Commission for patients with newly diagnosed multiple myeloma who are transplant-eligible. Available at: https://www.jnj.com/media-center/press-releases/darzalex-daratumumab-sc-based-quadruplet-regimen-approved-by-the-european-commission-for-patients-with-newly-diagnosed-multiple-myeloma-who-are-transplant-eligible. Last accessed: May 2025.8 Usmani S Z, et al. Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study. Oral presentation. 21st International Myeloma Society (IMS) Annual Meeting. September 25 – 28, 2024.9 Clinicaltrials.gov. A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy. NCT03652064. Available at: https://clinicaltrials.gov/study/NCT03652064?term=NCT03652064&cond=Multiple%20Myeloma&rank=1&a=63. Last accessed: May 2025.10 European Commission approves Johnson & Johnson's subcutaneous DARZALEX® (daratumumab)-based quadruplet regimen for the treatment of patients with newly diagnosed multiple myeloma, regardless of transplant eligibility. Available at: https://www.jnj.com/media-center/press-releases/european-commission-approves-johnson-johnsons-subcutaneous-darzalex-daratumumab-based-quadruplet-regimen-for-the-treatment-of-patients-with-newly-diagnosed-multiple-myeloma-regardless-of-transplant-eligibility. Last accessed: May 2025.11 Johnson & Johnson [data on file]. RF-430506. Number of patients treated with DARZALEX® worldwide as of 30 June 2024.12 Janssen EMEA. European Commission Grants Marketing Authorisation for DARZALEX® (Daratumumab) Subcutaneous Formulation for All Currently Approved Daratumumab Intravenous Formulation Indications. Available at: http://www.businesswire.com/news/home/20200604005487/en/European-Commission-GrantsMarketingAuthorisation-for-DARZALEX%C2%AE%E2%96%BC-daratumumab-SubcutaneousFormulation-for-all-CurrentlyApproved-Daratumumab-Intravenous-Formulation-Indications. Last accessed: May 2025.13 Moreau P, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, openlabel, phase 3 study. Lancet 2019;394(10192):29-38.14 Facon T, et al. MAIA Trial Investigators. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N Engl J Med 2019;380(22):2104-2115.15 Mateos MV, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. The Lancet 2020;395:P132-141.16 Dimopoulos MA, et al. APOLLO Trial Investigators. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol 2021;22(6):801-812.17 Palladini G, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood 2020;2;136(1):71-80.18 Chari A, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood 2017;130(8):974-981.19 Bahlis NJ, et al. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia 2020;34(7):1875-1884.20 Mateos MV, et al. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. Clin Lymphoma Myeloma Leuk 2020;20(8):509-518.21 Abdi J, et al. Drug resistance in multiple myeloma: latest findings on molecular mechanisms. Oncotarget 2013;4(12):2186-2207.22 American Society of Clinical Oncology. Multiple myeloma: introduction. Available at: https://www.cancer.org/cancer/types/multiple-myeloma/if-you-have-multiple-myeloma. Last accessed: May 2025.23 ECIS - European Cancer Information System. Estimates of cancer incidence and mortality in 2022, by country. Multiple myeloma. Available at: https://ecis.jrc.ec.europa.eu/explorer.php?$0-0$1-All$2-All$4-1,2$3-51$6-0,85$5-2022,2022$7-7$CEstByCountry$X0_8-3$X0_19-AE27$X0_20-No$CEstBySexByCountry$X1_8-3$X1_19-AE27$X1_-1-1$CEstByIndiByCountry$X2_8-3$X2_19-AE27$X2_20-No$CEstRelative$X3_8-3$X3_9-AE27$X3_19-AE27$CEstByCountryTable$X4_19-AE27. Last accessed: May 2025.24 Bhatt P, Kloock C, Comenzo R. Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse. Curr Oncol. 2023;30(2):2322-2347.25 Hernández-Rivas JÁ, et al. The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies. Biomark Res. 2022;10(1):1-23.26 Gavriatopoulou M, et al. Metabolic Disorders in Multiple Myeloma. Int J Mol Sci. 2021;22(21):11430.27 American Cancer Society. Multiple myeloma: early detection, diagnosis and staging. Available at: https://www.cancer.org/content/dam/CRC/PDF/Public/8740.00.pdf. Last accessed: May 2025.
CP-520659
May 2025
CONTACT: Media contact: Jenni Mildon jmildon@its.jnj.com +44 7920 418 552 Investor contact: Lauren Johnson investor-relations@its.jnj.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
ALSPs Exploit Technology to Meet Rising Demand for Affordable, Efficient Legal Services
The global Alternative Legal Service Providers market is poised to grow from USD 24.49 billion in 2024 to USD 49.61 billion by 2033, at a CAGR of 8.3%. Driven by demand for cost-effective, tech-enabled solutions, ALSPs leverage AI and automation to outperform traditional law firms in efficiency and pricing. Alternative Legal Service Providers Market Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The "Alternative Legal Service Providers Market Size, Share & Trends Analysis Report By Services (Taxation, Real Estate, Litigation, Bankruptcy, Labor/Employment, Corporate), By Billing Type (Hourly Billing, Flat Fee Billing), By Region and Segment Forecasts, 2025 - 2033" has been added to offering. The global alternative legal service providers (ALSP) market is set to expand significantly, with its value estimated at USD 24.49 billion in 2024 and expected to reach USD 49.61 billion by 2033, growing at a CAGR of 8.3% from 2025 to 2033 The surge in demand is fueled by clients seeking cost-effective and technologically advanced legal solutions, which offer improved efficiency and transparency over traditional law firms. Clients increasingly favor cost-efficient legal services as conventional firms' high billing practices drive them towards more affordable alternatives delivering quality legal work at reduced expenses. ALSPs are adept at minimizing costs through technology, process optimization, and innovative staffing strategies, ensuring value and efficiency without compromising services. This drive for cost-effectiveness is especially relevant within the tightening corporate legal budgets and scrutiny on legal expenditures, propelling organizations to outsource routine and specialized legal tasks to ALSPs. The dynamic evolution and adoption of legal technology are also key drivers of the ALSP industry's expansion. Advanced tools like AI-driven contract analysis, e-discovery platforms, and workflow automation facilitate quicker, more accurate, and scalable services. These tech innovations reduce mistakes, shorten processing times, and enhance precision in handling complex tasks. With law firms and in-house legal teams increasingly integrating such technologies, ALSPs are positioned as preferred collaborators delivering tech-driven solutions, boosting industry growth. Globally, the expanding regulatory landscape has escalated compliance complexities and volumes. ALSPs provide efficient compliance support, risk management, and monitoring services, offering tailored solutions that swiftly adapt to regulatory changes. Their expertise in compliance is crucial for businesses aiming to maintain compliance without straining internal resources, significantly propelling the sector forward. The rise in collaboration between traditional law firms and ALSPs further propels the market. Legal practices recognize the value ALSPs add by handling routine or technology-intensive tasks, allowing firms to concentrate on high-value work. Partnerships and joint ventures are increasing, driven by a strategic need to optimize efficiency, cut costs, and diversified service offerings. Such cooperation not only legitimizes the ALSP market but also fosters hybrid models that merge conventional legal prowess with innovative methodologies, fueling growth and diversification. Why should you buy this report? Comprehensive Market Analysis: Insight into the global market across major regions and segments. Competitive Landscape: Understand the global market presence of key players. Future Trends: Identify pivotal trends and drivers shaping the global market. Actionable Recommendations: Leverage insights to uncover new revenue streams and guide decisions. Key Attributes: Report Attribute Details No. of Pages 150 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $24.49 Billion Forecasted Market Value (USD) by 2033 $49.61 Billion Compound Annual Growth Rate 8.3% Regions Covered Global Companies Featured Axiom Law Elevate Services, Inc. Integreon Managed Solutions Limited Lawyers On Demand (LOD) QuisLex, Inc. Morae Global Corporation Obelisk Support Solutions Limited KPMG Ernst & Young Global Limited UnitedLex Corporation Global Alternative Legal Services Providers Market Report Segmentation Services Outlook (Revenue, USD Billion, 2021 - 2033) Taxation Real Estate Litigation Bankruptcy Labor/Employment Corporate Billing Type Outlook (Revenue, USD Billion, 2021 - 2033) Hourly Billing Flat Fee Billing Contingency Fee Billing Subscription Billing Regional Outlook (Revenue, USD Billion, 2021 - 2033) North America: U.S., Canada, Mexico Europe: Germany, UK, France Asia Pacific: China, Japan, India, South Korea, Australia Latin America: Brazil Middle East and Africa: UAE, Saudi Arabia, South Africa For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Alternative Legal Service Providers Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
12 minutes ago
- Yahoo
COFICERT : ORGANIZATION OF AN INTERNATIONAL CEREMONY FOR THE AWARDING OF FINANCIAL AND NON-FINANCIAL COMPLIANCE CERTIFICATES AT EURONEXT
ORGANIZATION OF AN INTERNATIONAL CEREMONY FOR THE AWARDING OF FINANCIAL AND NON-FINANCIAL COMPLIANCE CERTIFICATES AT EURONEXT On Tuesday, June 25, COFICERT, in partnership with IGSF, hosted an official ceremony to award financial and non-financial compliance certificates at the Euronext headquarters, located at the Paris Stock Exchange. Several delegations from institutions known for their dedication to compliance and responsible finance, representing almost fifteen nations, came together for this event. A number of organisations received compliance certificates in line with globally accepted standards, such as the AML 30001® Standard (AML/CFT 2025 version), which is focused on counter-terrorism financing and anti-money laundering, and the MSI 20000® Standard, which is focused on governance and financial quality. The ISO 37001® Standard, which focusses on anti-corruption, and the ESG 1000® Standard, which is dedicated to governance and quality of non-financial governance structures, were also emphasised during the event. The ceremony was attended by Véronique de la Bachelerie, President of IGSF, Jérôme Gacoin, President of COFICERT, and Souheil Skander, CEO of COFICERT. It also gathered representatives from the European Commission, the World Bank, the OECD, and the EU Global Facility on AML/CFT, reflecting the growing importance attached to certification to these standards and international cooperation between Europe, Africa, and the Middle East in these areas. This convergence around a shared normative framework demonstrates a collective will to foster greater transparency and a standardized language, serving as a catalyst for universal compliance. The companies certified during this ceremony belong to strategic sectors, placing them in a position to drive change within their respective countries or regions, thereby fostering the widespread adoption of best practices and contributing to enhanced integrity across the financial system. Notably, the companies that made the trip to Paris are among the leading financial and economic players on the African continent. West and Central Africa were represented by BSIC and NSIA Bank (Benin, Guinea, Togo, Senegal), as well as BGFIBank Group (Côte d'Ivoire, Gabon, Cameroon, DRC), all of which hold prominent regional positions. North Africa was well represented by Tunisia, Morocco, and Egypt, with leading institutions such as Bank of Tunisia, Tunisie Leasing & Factoring, Tunisie Valeurs, Hannibal Lease, BSB TOYOTA, Attawfiq Microfinance, and Alamana Microfinance. The diversity of these profiles illustrates the inclusive and structuring purpose of the MSI 20000® Standard, uniting key transformational actors at a regional level and compliance drivers at an international level. The organization of this event, along with the presence of official delegations and international organizations, underscores the growing importance attributed to financial and non-financial compliance as a pillar of performance, responsibility, and ultimately, value creation. Ms. Véronique de la Bachelerie, President of IGSF, emphasized: 'The financial and non-financial certifications standardized by IGSF and ISO provide a guarantee of confidence in the financial sustainability of a company (MSI 20000), a guarantee of confidence in the quality of its governance and its risk management policies regarding financial crime through anti-money laundering and counter-terrorism financing (AML 30001), the fight against corruption (ISO 37001), and finally a guarantee of confidence in its ability to address all environmental and social challenges through the quality of its non-financial governance. More broadly, this contributes to the company's sustainability – that is the value proposition of ESG 1000, in support of sustainable finance.' Mr. Jérôme Gacoin, President of COFICERT, stated: 'We have just experienced a moment that is both symbolic and foundational. Symbolic, because the adoption of these standards reflects the commitment of companies and institutions to comply with demanding, internationally recognized standards. Foundational, because it contributes to a dynamic of trust, transparency, and responsibility at both the European and global levels. Furthermore, the Paris Stock Exchange, a crossroads of markets and investments, perfectly embodies COFICERT's mission: to raise standards, secure economic relationships, and recognize the value of committed organizations.' Mr. Souheil Skander, CEO of COFICERT, added: 'The companies certified to the MSI 20000, ISO 37001, and AML 30001 standards have successfully turned what was once a constraint into an opportunity and a powerful lever of attractiveness and value creation. Certifications today serve as true benchmarks – they are closely observed and highly valued. They offer undeniable competitive and differentiation advantages, effectively acting as a qualitative filter. These certifications have become tools of assurance, opportunity, and synergy for business development.' IGSF (International Group for Sustainability Finance) is a non-profit NGO based in Luxembourg, whose activities aim to channel and organise international efforts in financial and extra-financial standard-setting. As a standard-setting body, IGSF operates along two main axes: first, the technical organization of standards related to financial and extra-financial governance; and second, the dissemination of standards and best practices. The issues addressed by IGSF include financial governance, the fight against financial crime and the social responsibility of companies and organisations of all types. COFICERT is a French certification body specializing in financial and non-financial certifications, operating in nearly 50 countries across 3 continents. COFICERT is recognized for its expertise in governance, anti-financial crime, and sustainable finance. It certifies organizations in areas related to sound financial governance (MSI 20000), extra-financial governance (ESG 1000), anti-money laundering and counter-terrorism financing (AML 30001), and anti-corruption (ISO 37001). COFICERTPress Contact+33 (0)1.78.91.06.00presse@ AELIUM FinancialCommunicationSolène KENNIS skennis@ Attachment EN_CP_COFICERT-EURONEXT-IGSF_VO
Yahoo
12 minutes ago
- Yahoo
U.S. Acute External Ventricular Drain Market Analysis Report 2025-2030 Featuring Medtronic, Integra, LifeSciences, Anuncia Medical, Natus, Fuji Systems, B Braun/Aesculap, Boston Scientific, Abbott
The U.S. acute external ventricular drain market, valued at USD 86.5 million in 2024, is set to grow at a CAGR of 7.9% from 2025 to 2030. Growth is driven by increased demand for noninvasive neurosurgeries, technological innovations, and rising healthcare spending. Favorable reimbursement policies and an aging population further fuel market expansion. U.S. Acute External Ventricular Drain Market Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The "U.S. Acute External Ventricular Drain Market Size, Share & Trends Analysis Report By Application (Traumatic Brain Injury, Subarachnoid Hemorrhage, Intracerebral Hemorrhage), By Patient Type (Pediatric, Adult), And Segment Forecasts, 2025 - 2030" report has been added to U.S. acute external ventricular drain market size was valued at USD 86.5 million in 2024 and is projected to grow at a CAGR of 7.9% from 2025 to 2030 The growth is expected to be driven by the rising prevalence of non-traumatic hydrocephalus, increased demand for minimal or noninvasive neurosurgeries, and the rising adoption of technologically improved devices. With the growing incidence of accidents, sports injuries, and strokes, the demand for external ventricular drain (EVD) procedures is rising steadily. As the aging population expands, the prevalence of conditions like strokes and aneurysms rises, further boosting the need for EVD procedures. For instance, according to the World Bank Group, the total population aged 65 and above in the U.S. was 49.98 million in 2018, increasing to 58.38 million in 2023. In addition, advancements in healthcare infrastructure and the rising number of emergency and trauma centers equipped to handle acute neurological cases contribute to market innovations in EVD systems, such as improved catheter designs, antimicrobial coatings, and integrated monitoring capabilities, enhance patient outcomes and reduce infection risks, making these devices more appealing to healthcare providers. Hospitals and clinics increasingly adopt these advanced EVD systems to improve treatment efficiency and minimize complications. Moreover, the growing emphasis on minimally invasive neurosurgical techniques supports the demand for EVDs, as they offer a less invasive solution for managing CSF drainage than traditional surgical factor fueling market expansion is the rising healthcare expenditure in the U.S., coupled with favorable reimbursement policies for neurological procedures. According to the Centers for Medicare & Medicaid Services, U.S. healthcare spending increased by 7.5% in 2023, reaching USD 4.9 trillion, which amounts to USD 14,570 per person. Insurance coverage for EVD placements and related treatments ensures broader patient access, encouraging hospitals to invest in these devices. Furthermore, increased physician awareness about the benefits of early and effective CSF management in critical care settings drives higher adoption rates.U.S. Acute External Ventricular Drain Market Report SegmentationApplication Outlook (Revenue, USD Million, 2018 - 2030) Traumatic Brain Injury Subarachnoid hemorrhage Intracerebral hemorrhage Other Non-Traumatic Hydrocephalus conditions Patient Type Outlook (Revenue, USD Million, 2018 - 2030) Pediatric Adult Why should you buy this report? Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments. Competitive Landscape: Explore the market presence of key players worldwide. Future Trends: Discover the pivotal trends and drivers shaping the future of the global market. Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions. Key Attributes: Report Attribute Details No. of Pages 80 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $86.5 Million Forecasted Market Value (USD) by 2030 $135.8 Million Compound Annual Growth Rate 7.9% Regions Covered United States U.S. Acute External Ventricular Drain Market Variables, Trends & Scope Market Lineage Outlook Parent market outlook Related/ancillary market outlook Market Dynamics Market driver analysis Market restraint analysis U.S. Acute External Ventricular Drain Market Analysis Tools Industry Analysis - Porter's PESTEL Analysis U.S. Acute External Ventricular Drain Market: Pipeline Analysis Companies Featured Medtronic Integra LifeSciences Corporation Anuncia Medical, Inc. Natus Fuji Systems B Braun/Aesculap Boston Scientific Abbott For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment U.S. Acute External Ventricular Drain Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio